GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OSE Immunotherapeutics SA (XPAR:OSE) » Definitions » Other Financing

OSE Immunotherapeutics (XPAR:OSE) Other Financing : €-5.44 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is OSE Immunotherapeutics Other Financing?

OSE Immunotherapeutics's Other Financing for the six months ended in Dec. 2023 was €-5.44 Mil.

OSE Immunotherapeutics's Other Financing for the trailing twelve months (TTM) ended in Dec. 2023 was €-5.44 Mil.

OSE Immunotherapeutics Other Financing Historical Data

The historical data trend for OSE Immunotherapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OSE Immunotherapeutics Other Financing Chart

OSE Immunotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.16 -1.20 - -0.14 -5.44

OSE Immunotherapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 - -0.14 - -5.44

OSE Immunotherapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-5.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OSE Immunotherapeutics Other Financing Related Terms

Thank you for viewing the detailed overview of OSE Immunotherapeutics's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

OSE Immunotherapeutics (XPAR:OSE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OSE Immunotherapeutics SA (XPAR:OSE) » Definitions » Other Financing
Comparable Companies
XPAR:ADOC XPAR:MAAT XPAR:ALSEN XPAR:ALVAL XPAR:ALCLS XPAR:ALACT XPAR:TNG XPAR:ABNX XPAR:GNFT XPAR:ALGEN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
6OP:Germany
Address
22, Boulevard Benoni Goullin, Nantes, FRA, 44200
Website
http://www.ose-immuno.com
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.

OSE Immunotherapeutics (XPAR:OSE) Headlines

No Headlines